Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Allakos
Biotech
Allakos drops lead asset after midphase flops, halves headcount
Allakos failed to show lirentelimab improves outcomes in three phase 3 trials—and just added two midphase studies to its list of flops.
Nick Paul Taylor
Jan 16, 2024 9:26am
Allakos' failed phase 3 EoDyssey sinks gastrointestinal program
Sep 9, 2022 9:32am
Alta raises $130M for its new biotech VC fund, missing its goal
Jun 13, 2018 2:32pm
Allergy, inflammation player Allakos reels in $100M series B
Dec 13, 2017 5:09pm
